CAPRICOR THERAPEUTICS, INC. (CAPR) - Dilution Analysis

10-Q filing | 57.4M shares outstanding

10-K filing | 57.5M shares outstanding

8-K filing: Capricor Therapeutics, Inc. announced a public offering of 6,000,000 shares of common stock at a price of $25.00 per share, with an option for the underwriters to purchase up to 900,000 additional shares. ($150.0M proceeds)

S-3 filing: CAPRICOR THERAPEUTICS, INC. may offer and sell up to $300,000,000 in the aggregate of any combination of common stock, preferred stock, and debt securities from time to time in one or more offerings.

10-Q filing | 45.7M shares outstanding

10-Q filing | 45.6M shares outstanding

10-K filing | 45.6M shares outstanding

10-Q filing | 33.1M shares outstanding

S-3 filing: This prospectus relates to the resale by the selling stockholder of up to 2,798,507 shares of common stock of Capricor Therapeutics, Inc.

8-K filing: Capricor Therapeutics, Inc. entered into an underwriting agreement with Piper Sandler & Co. and Oppenheimer & Co. Inc. for a public offering of 4,412,000 shares of common stock at $17.00 per share, with an option for the underwriters to purchase up to 661,800 additional shares.

S-3/A filing: This S-3/A filing by Capricor Therapeutics, Inc. relates to a shelf offering of up to $150,000,000 in the aggregate of common stock, preferred stock, and debt securities. The filing also discusses potential offerings of common or preferred stock upon conversion or exercise of other securities.

8-K filing: Capricor Therapeutics, Inc. announced a private placement to Nippon Shinyaku and sales under its at-the-market program. ($68.9M proceeds)

8-K filing: Capricor Therapeutics, Inc. issued and sold 2,798,507 shares of common stock to Nippon Shinyaku in a private placement at a price of $5.36 per share for gross proceeds of approximately $15.0 million. ($15.0M proceeds)

10-Q filing | 31.8M shares outstanding

S-3 filing: Capricor Therapeutics, Inc. is filing an S-3 to offer and sell up to $150,000,000 in the aggregate of common stock, preferred stock, and debt securities.

10-Q filing | 31.4M shares outstanding

10-K filing | 31.1M shares outstanding

10-Q filing | 25.8M shares outstanding

8-K filing: Capricor Therapeutics, Inc. entered into a securities purchase agreement to sell and issue 4,935,621 shares of common stock and warrants to purchase 4,935,621 shares in a registered direct offering for gross proceeds of approximately $23 million. ($23.0M proceeds)

10-Q filing | 25.3M shares outstanding

10-Q filing | 25.2M shares outstanding

10-K filing | 24.6M shares outstanding

10-Q filing | 24.4M shares outstanding

10-Q filing | 24.3M shares outstanding

10-Q filing | 24.3M shares outstanding

10-K filing | 23.1M shares outstanding

10-Q filing | 23.1M shares outstanding

10-Q filing | 22.9M shares outstanding

S-3/A filing: Capricor Therapeutics may offer and sell up to $150,000,000 in the aggregate of any combination of common stock, preferred stock, and debt securities.

10-Q filing | 22.9M shares outstanding

S-3 filing: CAPRICOR THERAPEUTICS, INC. is offering $150,000,000 in the aggregate of any combination of common stock, preferred stock, and debt securities from time to time in one or more offerings.

10-K filing | 22.8M shares outstanding

10-Q filing | 20.4M shares outstanding

10-Q filing | 19.7M shares outstanding

10-Q filing | 14.3M shares outstanding

S-3 filing: This prospectus relates to the resale by the selling stockholders named herein of up to 4,200,000 shares of our common stock comprised of warrants to purchase up to 4,000,000 shares of our Common Stock with an exercise price of $1.27 per share and placement agent warrants to purchase up to 200,000 shares of our Common Stock with an exercise price of $1.5313 per share.

10-K filing | 8.9M shares outstanding

8-K filing: Capricor Therapeutics issued 531,173 shares of common stock and warrants to purchase shares of common stock in December Offering, exercised pre-funded warrants, and entered into an exercise agreement with a holder of existing warrants, issuing 4,000,000 additional warrants in connection with the exercise of 4,000,000 existing warrants. ($4.9M proceeds)